Rahul Banerjee/X
May 23, 2025, 07:11
Rahul Banerjee Reacts to FDA ODAC News on Smoldering Myeloma Decision-Making
Rahul Banerjee, Assistant Professor at Fred Hutchinson Cancer Center at the University of Washington, posted on X:
“Excellent news from FDA ODAC – thanks to AQUILA team and to all the physicians and patients who testified today!
Shared decision-making between patients and MDs will remain key to high-risk smoldering myeloma, and hopefully decision-making will involve daratumumab at some point.”
More posts featuring Rahul Banerjee on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 5, 2025, 20:31
Jul 5, 2025, 20:15
Jul 5, 2025, 20:00
Jul 5, 2025, 19:18
Jul 5, 2025, 18:52
Jul 5, 2025, 18:38